Please login to the form below

Not currently logged in
Email:
Password:

omecamtiv

This page shows the latest omecamtiv news and features for those working in and with pharma, biotech and healthcare.

Amgen agrees to take Cytokinetics' heart failure drug into phase III

Amgen agrees to take Cytokinetics' heart failure drug into phase III

Omecamtiv is the first in a new class of drugs designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance. ... function when omecamtiv mecarbil was given twice-daily over a 20-week period.

Latest news

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Rounding out a trio of new cardiology products at the biopharma company is omecamtiv mecarbil or AMG 423 for acute heart failure, for which phase II data on an oral formulation

  • Amgen drug misses endpoint in acute heart failure trial Amgen drug misses endpoint in acute heart failure trial

    Amgen drug misses endpoint in acute heart failure trial. Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure. ... It's a blow for both Amgen and its marketing partner Servier, which obtained from Amgen last month an

  • Amgen buys US rights to Servier’s Procoralan Amgen buys US rights to Servier’s Procoralan

    Amgen buys US rights to Servier’ s Procoralan. Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe. ... In return, Servier obtained an exclusive option to commercialise Amgen's omecamtiv mecarbil

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2). ... rights in Europe for omecamtiv mecarbil. †

  • Pharma deals during July 2013 Pharma deals during July 2013

    the US, and Servier receives an option to omecamtiv mecarbil for Europe. ... Omecamtiv mecarbil is currently in phase II trials for acute and chronic heart failure and is the most advanced drug candidate coming out of Amgen's collaboration with

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    129. Cytokinetics / Amgen. Extension of existing licence to Japan. Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics